This site is initiated and funded by Recordati Rare Diseases. This website is intended for members of the public in the UK and Ireland.

Disclosure

All of our interactions are guided by what is right for the patient and we ensure transparency in all areas of our business and are committed to compliance and ethics.

We understand that transparency is essential to building and maintaining confidence and trust in our medicines and our work.

 

United Kingdom

We are members of the Association of the British Pharmaceutical Industry (ABPI) and we abide by the ABPI Code of Practice for the Pharmaceutical Industry, which has detailed requirements to ensure member companies operate in a responsible, ethical and professional manner.

 

This includes how we work with healthcare professionals, members of the public, including patients and journalists, healthcare organisations and patient organisations.

 

Please visit the ABPI website, known as Disclosure UK https://search.disclosureuk.org.uk for further information on payments made by Recordati to Healthcare Professionals, Other Relevant Decision Makers and Healthcare organisations.

 

Information on payments made to members of the public, including patients and journalists, and patient organisations is shown below.

 

Republic of Ireland

We are not members of the Irish Pharmaceutical Healthcare Association (IPHA). However, we do abide by the principles of the IPHA Code of Practice.
 
From 2026 onwards, information on payments to Irish healthcare professionals, healthcare organisations and patient organisations can be located below.
Financial and non-financial support provided to UK members of the public, including patients and journalists, and patient organisations
2022 DOWNLOAD
2023 DOWNLOAD
2024 DOWNLOAD
Methodological Notes

Here you can download the methodological note prepared to support disclosure of transfers of value for Recordati Rare Diseases UK Ltd. (RRD) and Recordati UK Ltd. (RUK) for the specified calendar year:

2022 Methodological Note RRD
2023 Methodological Note RRD
2024 Methodological Note RRD
2024 Methodological Note RUK
Financial and non-financial support provided to UK members of the public, including patients and journalists, and patient organisations
Financial and non-financial support provided to healthcare professionals, healthcare organisations, members of the public, including patients and journalists, and patient organisations located in the Republic of Ireland
Methodological notes prepared to support disclosure of transfers of value
Company Reports
  • Net Zero Statement – click here
  • Environmental, Sustainability & Growth (ESG) Statement – click here
  • Modern Slavery Statement RRD– click here
  • Modern Slavery Statement RUK – click here
  • PPN Carbon Reduction Plan RRD– click here
  • PPN Carbon Reduction Plan RUK– click here
  • Recordati UK Ltd Tax Strategy Statement– click here
  • Recordati Rare Disease UK Ltd Tax Strategy Statement– click here

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to support.microsoft.com

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to clinicaltrials.gov

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to hpra.ie

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to yellowcard.mhra.gov.uk

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to search.disclosureuk.org.uk

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to support.apple.com

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to support.mozilla.org

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to support.google.com

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to youronlinechoices.com

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to edpb.europa.eu

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to edoeb.admin.ch

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to ico.org.uk

ACCEPT
GO BACK

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to careers.recordati.com

ACCEPT
GO BACK
Recordati for the planet
A clean environment is essential for people’s well-being: the health of the planet and the health of people is tightly interconnected. Environmental elements, such as air, water, land and climate, all have an impact on the well-being of humans. Placing a focus on people’s health and being sustainable therefore also means prioritising environmental protection and a responsibility towards future generations. This is why the Group ensures that it conducts business in a socially responsible manner and in accordance with sustainable practices, national and international laws, and the expectations of stakeholders.
Recordati for the community
We believe that contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely the fulfilment of company obligations or professional duty, but rather a moral imperative, an essential part of a healthy business capable of growth but at the same time able to support and develop the community in which it operates and make its employees proud.
Value and diversity of our people
At Recordati, we believe in equal opportunities and we guarantee that everyone can achieve their potential. We see diversity as a value and will not tolerate any discrimination based on ethnicity, nationality, gender, sexual orientation, disability, age, political or religious belief, or any other personal characteristics. At Recordati, we work hard to create a safe and inclusive work environment, where we all have our rights to physical and psychological integrity respected on a daily basis, as well as our right to freedom of opinion and association. We recognise that we each have a role to play in the success of our business and we implement staff development policies through which everyone’s contribution and achievements can be appropriately rewarded.
Multiple opportunities
Recordati is uniquely structured to bring treatment options across specialty and primary care, consumer healthcare, and rare diseases. We have fully integrated operations across research and development, chemical and finished product manufacturing through to commercialisation and licensing.
Luigi Longinotti
Managing Director and General Manager EMEA

Luigi Longinotti is Managing Director and General Manager for EMEA at Recordati Rare Diseases, leading the European and Middle Eastern Commercial Operations. He is responsible for Marketing, Medical, Market Access, Regulatory, Manufacturing and Logistics, as well as the enabling functions to support the business, including Compliance and Quality.

 

He joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. In such a role he has been responsible for driving the growth of the rare disease portfolio at Recordati, with his duties ranging from business development to strategic marketing and pipeline project management.

 

Before he joined Recordati, he held senior business and corporate development roles at Chiesi Farmaceutici and Menarini Group where he executed several key asset deals and transactions.

Luigi gained a degree in Economics from the University of Florence and a Master’s degree in Business Innovation from Sant’Anna School of Advanced Studies in Pisa.

Bruno Parenti
Head of LAC Region, Head of Global Endocrinology Franchise

Bruno Parenti is Head of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific and Russia. He has been in this position since 2011, where he spearheaded the expansion of operations around the globe. He recently assumed the additional role of Head of Global Endocrinology Franchise, establishing the new HQ in Basel and building a dedicated organization.

 

Prior to these positions, Bruno spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.

Mohamed Ladha
President and General Manager, North America

Mohamed Ladha is the President and General Manager at Recordati Rare Diseases where he is   responsible for the US and Canadian business. During his career,  Mohamed has held numerous leadership positions globally in hematology/oncology and specialty care to oversee business in the US, Canada, EU, China, Emerging Markets, and Japan.

 

Mohamed  joins Recordati Rare Diseases from Oncopeptides, where he was the General Manager and Executive Vice President for the US Region Business Unit. Prior to Oncopeptides, he served in a series of leadership positions of increasing responsibility at companies including Vertex Pharmaceuticals, Pfizer, Schering-Plough, Merck & Company, Hospira, ARIAD Pharmaceuticals, Takeda Oncology, and Tocagen. He started his career in basic science research focused in oncology at the Dana-Farber Cancer Institute.

 

Mohamed graduated from Hampshire College with a Bachelor of Arts degree. He also holds professional/graduate degrees from Harvard University’s Kennedy School of Government and Northwestern University’s Kellogg School of Management.

 

Changing to first name to be consistent with bio below, also feel that first name as opposed to Mr has a more informal and friendly tone.   [EC1]

Scott Pescatore
Executive Vice President

Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.

He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.

 

He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.

 

Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site